New oral anticoagulants: a practical guide for clinicians

被引：0
作者：
Ann K. Wittkowsky
机构：
[1] University of Washington School of Pharmacy,Anticoagulation Services
[2] University of Washington Medical Center,undefined
来源：
Journal of Thrombosis and Thrombolysis | 2010年 / 29卷
关键词：
Anticoagulation; Dabigatran; Rivaroxaban; Apixaban;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The search for an oral anticoagulant with acceptable efficacy and safety in the treatment and prevention of venous and arterial thromboembolism, but with practical advantages over warfarin, has been a focus of drug development for many years. Three oral agents, dabigatran, rivaroxaban, and apixaban, are nearing approval in the US. Their use in practice will be guided by the clinical trials available, as well as their pharmacokinetic and pharmacodynamic properties. Practitioners need to be fully aware of these characteristics in order to use these agents appropriately in clinical practice. This review compares the results of the phase 3 trials investigating these agents in the prevention of venous thromboembolism in patients undergoing orthopedic surgery, examines the reporting of bleeding complications in the trials, and highlights various practical considerations regarding their use in clinical practice.
引用
收藏
页码：182 / 191
页数：9
相关论文
共 73 条
  • [21] Eriksson BI(2008)Clinical pharmacokinetics and pharmacodynamices of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinetics 47 285-295
  • [22] Eriksson BI(2006)Effect of food, an antacid, and the H2 antagonist ranitidine on th absorption and BAY 59-7939 (rivaroxaban), an oral direct Xa inhibitor, in health subjects J Clin Pharmacol 46 549-558
  • [23] Borris LC(2008)Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Haemost 100 453-461
  • [24] Friedman RJ(2009)Apixaban metabolism and pharmacokinetics after oral administration in humans Drug Metab Disp 37 74-81
  • [25] Kakkar AK(2008)Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral direct factor Xa inhibitor—in patients undergoing major orthopedic surgery Clin Pharmacokinet 47 203-216
  • [26] Brenner B(2008)Apixaban, an oral direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies J Thromb Haemost 6 820-829
  • [27] Dahl OE(2005)The role of p-glycoprotein and organic anion-transporting polypeptides in drug interactions Drug Safety 28 789-801
  • [28] Lassen MR(2004)Functional interaction of intestinal CYP3A4 and p-glycoprotein Fund Clin Pharmacol 18 621-626
  • [29] Ageno W(undefined)undefined undefined undefined undefined-undefined
  • [30] Borris LC(undefined)undefined undefined undefined undefined-undefined
12345678